PLX Earnings Prediction
The chart below shows how PLX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PLX sees a -3.08% change in stock price 10 days leading up to the earnings, and a -0.54% change 10 days following the report. On the earnings day itself, the stock moves by -2.91%. This data can give you a slight idea of what to expect for the next quarter's release.
PLX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
17.96M
73.60%
33.29%
Gross Margin
53.37%
1.27%
78.97%
Operating Margin
22.22%
221.82%
-223.38%
Net Margin
18.02%
200.67%
-210.21%
EPS
0.04
233.33%
-233.33%
No Data Available
PLX Earnings Analysis
Protalix BioTherapeutics, Inc. Common Stock Corporation (PLX.A) Earnings Conference Call
Positive
Revenue Surge 75%: Revenue increased to $17.8 million for the three months ended September 30, 2024, a 75% increase compared to $10.2 million for the same period in 2023.
Sales Increase Contribution: Sales to Chiesi increased by $6.8 million, contributing significantly to the overall revenue growth.
Net Income Improvement: The company reported a net income of approximately $3.2 million for the three months ended September 30, 2024, compared to a net loss of $1.9 million for the same period in 2023.
Strong Liquidity Position: The total cash and cash equivalents were approximately $27.4 million at September 30, 2024, indicating strong liquidity.
Debt-Free Status Achieved: The company is now debt-free after repaying all outstanding principal and interest under the 7.5% senior secured convertible promissory notes.
Negative
Revenue Increase Analysis: Revenue from selling goods was $17.8 million during the three months ended September 30, 2024, an increase of $7.6 million or 75% compared to revenues of $10.2 million from three months ended September 30, 2023.
Cost of Goods Sold Increase: Cost of goods sold was $8.4 million for the three months ended September 30, 2024, an increase of $3.5 million or 71% from cost of goods sold of $4.9 million for the three months ended September 30, 2023.
R&D Expense Breakdown: Total research and development expenses were approximately $3 million, comprised of approximately $0.6 million subcontractor related expenses, approximately $1.6 million salary and related expenses, approximately $0.2 million of material related expenses, and approximately $0.6 million of other expenses.
R&D Expense Decrease: For the three months ended September 30, 2024, our total research and development expenses were approximately $3 million, compared to approximately $3.7 million for the three months ended September 30, 2023, a decrease of $0.7 million or 19%.
Net Income Improvement: Net income for the three months ended September 30, 2024 was approximately $3.2 million or $0.04 per share basic and $0.03 per share diluted compared to a net loss of $1.9 million or $0.03 per share basic and $0.04 per share diluted for the same period in 2023.
PLX FAQs
How does PLX typically perform around its earnings report dates?
Is Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PLX Earning Call Sentiment
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PLX.A
0%Positive
The earnings call presents a mixed picture: strong revenue growth and debt repayment are positives, but competitive pressures, clinical development risks, and supply chain challenges pose concerns. The Q&A section reveals management's uncertainty about trial specifics and market factors, which adds to the neutral sentiment. Despite revenue growth, the lack of new partnerships or guidance changes, coupled with economic factors, suggests a limited impact on stock price.
